The Cancer Therapeutics and Stratified Oncology group focuses on translational cancer research. Our goal is to integrate genomic information arising from both biological and clinical studies to uncover genetic and epigenetic mechanisms driving tumorigenesis and to develop novel approaches to tackle clinical problems such as therapeutic resistance and tumor recurrence. Our expertise includes both integrative cancer genomic analysis and defined biological systems with aims to discover novel biomarkers and therapeutic targets. We use Genome-to-Systems Biology strategies to understand and to manipulate complex cancer systems that are crucial for cancer cell fate decisions so as to achieve cellular outcomes and to develop novel therapies.

Our work involves active partnerships with the local clinical community to apply genomic technologies to directly characterize the molecular genetics of individual tumors, to identify genomic biomarkers that can predict patient responses to specific therapies and risk of disease progression. Through collaborations with clinicians, we seek to define novel approaches to molecularly stratify patients into distinct biological tumor subgroups and to understand the specific driver pathways underlying each subgroup. By matching these subgroups to appropriate therapies, we aim to shift the practice of cancer care from conventional "one-size-fits-all" approaches to personalized treatment strategies, thereby achieving the best possible outcomes for each individual patient.